What is B. Riley’s Estimate for MDGL Q3 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at B. Riley issued their Q3 2025 earnings estimates for shares of Madrigal Pharmaceuticals in a research note issued to investors on Monday, September 29th. B. Riley analyst W. Wood expects that the biopharmaceutical company will post earnings per share of ($0.66) for the quarter. B. Riley has a “Buy” rating and a $560.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2025 earnings at $0.83 EPS, FY2025 earnings at ($4.91) EPS, FY2026 earnings at $24.45 EPS, FY2027 earnings at $35.86 EPS and FY2028 earnings at $63.27 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share for the quarter, topping the consensus estimate of ($3.48) by $1.58. The firm had revenue of $212.80 million during the quarter, compared to analysts’ expectations of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The company’s revenue was up 1357.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($7.10) EPS.

Several other research firms have also commented on MDGL. TD Cowen increased their price target on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a “buy” rating in a research report on Tuesday, August 26th. JMP Securities boosted their price objective on shares of Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 20th. UBS Group reissued a “buy” rating and set a $523.00 target price (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a research report on Tuesday, August 12th. Cowen reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 26th. Finally, HC Wainwright started coverage on shares of Madrigal Pharmaceuticals in a report on Thursday, September 4th. They set a “buy” rating and a $500.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Madrigal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $495.88.

Madrigal Pharmaceuticals Price Performance

Shares of MDGL stock opened at $449.64 on Thursday. The stock’s 50-day moving average is $397.80 and its 200 day moving average is $336.76. Madrigal Pharmaceuticals has a 1-year low of $200.63 and a 1-year high of $463.63. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.11 and a quick ratio of 4.78. The company has a market cap of $9.98 billion, a P/E ratio of -34.99 and a beta of -1.02.

Insider Buying and Selling at Madrigal Pharmaceuticals

In related news, Director Paul A. Friedman sold 129,172 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $370.24, for a total transaction of $47,824,641.28. Following the completion of the transaction, the director directly owned 187,164 shares in the company, valued at approximately $69,295,599.36. This trade represents a 40.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rebecca Taub sold 43,263 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $355.69, for a total value of $15,388,216.47. Following the completion of the transaction, the director directly owned 461,044 shares of the company’s stock, valued at $163,988,740.36. The trade was a 8.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have bought 165,683 shares of company stock worth $61,921,142 and have sold 309,019 shares worth $112,705,072. Corporate insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several large investors have recently made changes to their positions in MDGL. Wealth Enhancement Advisory Services LLC acquired a new stake in Madrigal Pharmaceuticals during the fourth quarter valued at $210,000. California State Teachers Retirement System raised its position in shares of Madrigal Pharmaceuticals by 0.8% in the fourth quarter. California State Teachers Retirement System now owns 12,546 shares of the biopharmaceutical company’s stock worth $3,871,000 after acquiring an additional 105 shares during the period. GAMMA Investing LLC boosted its stake in shares of Madrigal Pharmaceuticals by 76,537.3% during the 1st quarter. GAMMA Investing LLC now owns 39,085 shares of the biopharmaceutical company’s stock worth $12,946,000 after acquiring an additional 39,034 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Madrigal Pharmaceuticals by 42.7% during the 1st quarter. Parallel Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 85 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Madrigal Pharmaceuticals by 7.9% in the 1st quarter. Rhumbline Advisers now owns 26,364 shares of the biopharmaceutical company’s stock valued at $8,733,000 after purchasing an additional 1,924 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.